Influence of Tropical Climate Conditions on the Quality of Antihypertensive Drugs from Rwandan Pharmacies by Twagirumukiza, Marc et al.
Am. J. Trop. Med. Hyg., 81(5), 2009, pp. 776–781
doi:10.4269/ajtmh.2009.09-0109
Copyright © 2009 by The American Society of Tropical Medicine and Hygiene
776
* Address correspondence to Luc Van Bortel, Heymans Institute of 
Pharmacology, Ghent University, De Pintelaan 185, Block B, 1st Floor, 
Ghent 9000, Belgium. E-mail: Luc.VanBortel@UGent.be 
 Influence of Tropical Climate Conditions on the Quality of Antihypertensive Drugs from 
Rwandan Pharmacies 
 Marc  Twagirumukiza ,  An  Cosijns ,  Eveline  Pringels ,  Jean Paul  Remon ,  Chris  Vervaet , and  Luc Van  Bortel * 
 Department of Internal Medicine, University Hospital, Kigali, Rwanda; Laboratory of Pharmaceutical Technology, Faculty of 
Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium 
 Abstract.  The objective of this study was to assess the quality of antihypertensive drugs and to investigate the influ-
ence of tropical storage conditions. Drug content and  in vitro dissolution tests were performed on 10 test formulations 
(from Rwanda) and 6 reference formulations (from Belgium or France) after purchase and after 6-month storage under 
long-term (25 ± 2°C and 60 ± 5% relative humidity [RH]) and accelerated (40 ± 2°C and 75 ± 5% RH) testing conditions. 
Twenty percent of test formulations were of substandard content at the time of purchase. After 6 months at accelerated 
testing conditions, 7 of 10 test formulations were substandard in content and 8 were substandard for the combined criteria 
of drug content and dissolution, whereas no reference drug became substandard. This study shows that, apart from some 
drugs being already substandard from purchase, accelerated testing conditions (simulating tropical climate) have deleteri-
ous effects on the majority of antihypertensive drug formulations found in the Rwandan market. 
 INTRODUCTION 
 Good-quality medicines are a prerequisite to successful 
treatment. Medicines can be substandard in quantity of active 
ingredient or in quality from purchase or become substan-
dard because of some degradation. 1 Poor stability may lead to 
drugs becoming toxic or increasingly inactive. 2 High tempera-
ture and relative humidity (RH) are the most important fac-
tors involved in drug degradation. 3 Although stability testing 
at high RH and temperature is mandatory in the drug devel-
opment process, 2,4 this should not exclude quality monitoring 
of medicines. However, in most of sub-Saharan African (SSA) 
countries, no systematic quality control is done at entrance to 
track substandards. 5 
 The substandard quality of medicines in developing coun-
tries has been largely reported. 6–9 However, the majority of 
these reports focus on medicines used in infectious diseases, 10–13 
which are commonly endemic in developing countries. Medi-
cines used in non-communicable disease (NCDs) such as 
hyper tension and other cardiovascular diseases (CVDs) have 
been poorly addressed. NCDs, specifically CVDs and hyper-
tension, are rarely on the health planning agenda in SSA, 14 
even if they are known now as real public health problems in 
SSA. 15 Projections show that, in a few years, CVD will dom-
inate the worldwide fatal illness, 16 which implies that more 
emphasis should be put on both risk factors to prevent the 
trend 17 and the treatment to reduce mortality. Hypertension is 
an important risk factor for CVD. The burden of hypertension 
was estimated at 79.8 million in SSA in 2002. 18 As for other 
conditions, in hypertension, the use of substandard quality 
drugs may result in treatment failure, 9 including fatal conse-
quences because of low drug content and toxic degradation 
products. 19 
 Rwanda and many sub-Saharan countries 2,20,21 import the 
majority of their drugs from various countries. The lack of 
systematic quality control and a liberalized drug distribution 
system create an environment favorable for introducing low-
quality drugs. In addition, the tropical climate conditions (high 
temperature and humidity) may alter the quality of drugs 
during distribution and storage. This study aimed to assess the 
quality of antihypertensive drugs from Rwandan pharmacies 
and to investigate the influence of tropical storage conditions 
on drug quality. 
 MATERIALS AND METHODS 
 A selection of the most commonly used antihypertensive 
drugs in Rwanda was listed. In total, 10 different formula-
tions of these drugs were found in 38 pharmacies. Pharmacies 
included all 4 public pharmacies (located in Kigali or Butare) 
and 34 randomly selected official private pharmacies in Kigali. 
A sample of each test formulation with remaining shelf life of 
at least 2 years was bought and kept in their original pack-
age until analysis.  Table 1 shows details of all formulations 
sampled. For each drug, the original brand purchased from a 
pharmacy in Belgium or France was used as reference. Before 
analysis, all reference and test formulations were coded to 
blind the investigator to the origin of the drug during the 
analysis. 
 Drug quality was studied by analyzing drug content and 
 in vitro dissolution. A substandard  in vitro dissolution pro-
file may indicate decreased bioavailability. 22,23 The drug con-
tent and  in vitro dissolution of all formulations were evaluated 
immediately after purchase and after 6-month storage. Drug 
storage was done according to the “International Conference 
on Harmonization (ICH) harmonized tripartite guidelines on 
Stability testing of new drug substances and products” 24,25 at 
long-term (25 ± 2°C and 60 ± 5% RH) and accelerated testing 
conditions (40 ± 2°C and 75 ± 5% RH), representing storage 
under Zone II and very hot/humid tropical (Zone IV) con-
ditions, 25 respectively. All drugs were analyzed using meth-
ods specified in the 2006 US Pharmacopeia and National 
Formulary (USP29–NF24) monograph of the respective 
drugs. 26 The assays were repeated three times, and results are 
the mean of three determinations. 
 For drug content, the USP29–NF24 26 acceptance limits are 
90–110% of the label claim, whereas for  in vitro dissolution, 
the limits of released amount of drug after a recommended 
period varies from one drug to another 26 as shown in  Table 3 . 
 The difference in dissolution characteristics between ref-
erence and test formulations and between test formulations 
at purchase and after 6 months of storage were compared 
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using the  f 2 similarity factor. 
27,28 Two dissolution profiles 
are considered pharmaceutically equivalent if the similarity 
factor is ≥ 50. 29 The similarity factor is a logarithmic reciprocal 
square root transformation of the sum of squared errors and is 
a measurement of the similarity between the two drug release 
curves. The  f 2 is given by the following formula 
29 : 
where  n stands for the number of time points and  t is the time 
point considered.  R equals the reference drug and  T is the 
drug to be tested. 
 Drug content was determined using high-pressure liquid 
chromatography (HPLC). The HPLC analyses were carried 
out using LaChrom equipment (Merck-Hitachi, Darmstadt, 
Germany). All drug standards were obtained from Sigma 
Aldrich (Steinheim, Germany). All reagents used during drug 
assay were of HPLC grade; the other reagents were of ana-
lytical grade. 26 For dissolution testing, a VanKel VK 7010 dis-
solution apparatus linked to a VK 8000 automatic sampler 
(VanKel Technology, Cary, NC) was used. A Lambda 12 UV/
VIS spectrophotometer (Perkin Elmer, Norwalk, CT) was 
used to determine the drug concentration in the dissolution 
media. 
 RESULTS 
 Except for two formulations of captopril (counting for 20% 
of test formulations), all antihypertensive formulations were 
within standards at purchase time in terms of content and  in 
vitro dissolution profiles. Although within standards, several 
formulations were already near the lower content acceptance 
limit at purchase. The two substandard captopril formulations 
Cetopril 25 mg and Cetopril 50 mg contained 38.6 (154.5%) 
and 26.5 mg (53.0%), respectively . 
 After 6-month storage at ambient conditions, the content 
of the two Cetopril formulations remained (as expected) sub-
standard. In addition, the content of the methyldopa formula-
tion from Kenya also became substandard. This formulation 
was already close to the lower acceptance limit at purchase 
time ( Table 2 ). On average, the content of test drug formula-
tions decreased 1.7 ± 1.1% after 6 months of storage. The larg-
est decrease (3.3%) was found for the atenolol (Catenol) from 
India, followed by hydrochlorothiazide (HCTZ) L&A from 
Kenya (3.0%), propranolol (Cepanolol; 2.4%) from India, 
methyldopa (Aldomet) from Pakistan (2.2%), and captopril 
50 mg (Cetopril, 2.1%) from India. The smallest decrease 
(0.2%) was found for HCTZ Cipla from India. 
 After 6-month storage at long-term testing conditions, the 
dissolution profiles were within the limits of good quality in 
all test and reference drugs ( Table 3 ). However, the formu-
lation of atenolol (Catenol) and propranolol (Cepanolol) 
showed a decreased drug dissolution profile compared with 
their  dissolution profiles at purchase ( Table 4 ). At 6 months 
under long-term testing conditions, 6 of 10 test formulations 
(60%) showed a lower dissolution profile than their reference 
drug formulation. 
 After 6-month storage at accelerated testing conditions apart 
from the two Cetopril formulations, the drug content of five 
other test formulations became substandard ( Table 2 ). On aver-
age, the content of test drug formulations decreased 8.5 ± 5.8%. 
The largest decrease (20.3%) was found for the methyldopa 
L&A from Kenya, followed by methyldopa (Aldomet; 15.5%) 
from Pakistan, and Captopril 25 mg (Cetopril) and atenolol 
(Catenol) (both 10.4%). The smallest decrease was found in 
both hydrochlorothiazide test formulations (2.8% and 4.3% for 
HCTZ Cipla from India and HCTZ L&A from Kenya, respec-
tively) and was on average 3.6 ± 1.1%. The methyldopa formula-
tions were by far the less stable formulations under accelerated 
testing conditions, with a loss of 17.9 ± 4.4% of their content 
within 6-month storage at accelerated testing conditions. In 
addition, the methyldopa formulation from Kenya (Methyldopa 
L&A) was macroscopically deteriorated ( Figure 1 ). 
 Table 1 
 Formulation samples analyzed of five antihypertensive drugs 
Drug Dose (mg) Packaging Batch number Manufacturer Origin Type of Rwandan pharmacy
Atenolol
Tenormin * 100 Blister 06I01 AstraZeneca Belgium NA
Betanorm 100 Plastic bottles 71183 L&A Kenya Public
Catenol 100 Blister MD 3583 Zydus Cadila India Private
Captopril
Capoten * 25 Blister A132 BMS Belgium NA
Capoten * 50 Blister A176 BMS Belgium NA
Captopril Denk 25 Blister 13587 Denk Pharma Germany Public
Cetopril 25 Blister KD-358/T25005 SPP India Private
Cetopril 50 Blister KD-358/T25105 SPP India Private
Hydrochlorothiazide (HCTZ)
Esidrex * 25 Blister B5133 Novartis France NA
HCTZ L&A 50 Plastic bottles 41155 L&A Kenya Private
HCTZ Cipla 50 Plastic bottles AST05008 Cipla India Public
Methyldopa
Aldomet Belgium * 250 Blister NE53510 MSD Belgium NA
Methyldopa L&A 250 Plastic bottles 45195 L&A Kenya Private
Aldomet Pakistan 250 Plastic bottles H 101 MSD Pakistan Pakistan Public
Propranolol
Inderal * 40 Blister 06K01 AstraZeneca Belgium NA
Cepanolol 40 Blister T 24905 SPP India Public
 * Reference drug. 
 NA = not applicable (samples not bought in Rwanda); MSD = Merck Sharp & Dohme; MSD Pakistan = Merck Sharp & Dohme Pakistan (Waseem Enterprises); SPP = Shreechem Pharmaceuticals 
PVT (India); L&A = Laboratory & Allied; BMS = Bristol-Myers Squibb. 
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 The dissolution profiles of six test formulations (60%) 
and none of the reference formulations became substandard 
after 6 months of accelerated testing conditions ( Table 3 ). All 
hydrochlorothiazide test formulations passed the dissolution 
test. The largest decrease in dissolution from time of purchase 
occurred in the two atenolol test formulations (18.7% and 
18.1% for Catenol and Betanorm, respectively) and 17.3% for 
methyldopa (Aldomet) from Pakistan. The smallest decrease 
(3.0%) occurred in hydrochlorothiazide Cipla from India. At 
6 months under accelerated testing conditions, the similarity 
factor of dissolution profiles was substandard, showing loss of 
pharmaceutical equivalence compared with purchase in 7 of 10 
test formulations and 1 (Inderal) of 6 reference formulations. 
Also, loss of pharmaceutical equivalence compared with the 
reference drug after 6 months under accelerated testing condi-
tions was found in 9 of 10 test formulations (90%;  Table 4 ). 
 Compared with 6 months under long-term testing condi-
tions, the dissolution profiles of all test drug formulations were 
 Table 3 
 Percentage of drug released by  in vitro dissolution 
Drug Dose (mg)
Dissolution duration 
(minutes)
Recommended amount of 
drug to be released (%)
Percentage of amount of released drug after a recommended period * 
 t = 0  t = 6 months
At purchase Long-term testing conditions Accelerated testing conditions
Atenolol
Tenormin † 100 30 ≥ 80 99.8 94.9 93.8
Betanorm 100 97.6 94.5  79.5 
Catenol 100 98.4 84.3  79.7 
Captopril
Capoten † 25 20 ≥ 80 96.6 96.4 94.0
Capoten † 50 99.2 98.4 95.0
Captopril Denk 25 98.8 98.4 90.7
Cetopril 25 94.1 88.5 85.6
Cetopril 50 82.4 81.4  79.4 
Hydrochlorothiazide (HCTZ)
Esidrex † 25 60 ≥ 60 98.5 97.7 97.4
HCTZ L&A 50 89.0 86.5 86.0
HCTZ Cipla 50 93.3 93.3 84.8
Methyldopa
Aldomet Belgium † 250 20 ≥ 80 97.9 96.8 96.3
Methyldopa L&A 250 88.5 84.3  78.8 
Aldomet Pakistan 250 96.5 95.4  79.2 
Propranolol
Inderal † 40 30 ≥ 75 89.0 89.0 86.7
Cepanolol 40 84.4 82.7  73.2 
 Substandard dissolution profiles are shown in bold. 
 * Percent of the amount released has been calculated taking into account the real amount of drug per tablet at that storage time. 
 † Reference drug. 
 Table 2 
 Percentage of claimed drug content 
Drug Dose (mg)
Percentage of claimed amount (the acceptance limit is 90–110%)
 t = 0  t = 6 months
At purchase Long-term testing conditions Accelerated testing conditions
Atenolol
Tenormin * 100 98.7 96.9 94.3
Betanorm 100 96.0 95.1 90.4
Catenol 100 97.1 93.8  86.7 
Captopril
Capoten * 25 98.8 98.9 97.3
Capoten * 50 98.0 96.7 95.7
Captopril Denk 25 96.4 95.7 94.7
Cetopril 25  154.5  154.2  144.1 
Cetopril 50  53.0  50.9  44.5 
Hydrochlorothiazide (HCTZ)
Esidrex * 25 92.7 92.6 91.3
HCTZ L&A 50 94.3 91.3 90.0
HCTZ Cipla 50 90.2 90.0  87.4 
Methyldopa
Aldomet Belgium * 250 97.3 96.3 94.9
Methyldopa L&A 250 90.6  89.1  70.3 
Aldomet Pakistan 250 92.2 90.0  76.7 
Propranolol
Inderal * 40 103.2 100.7 95.4
Cepanolol 40 92.5 90.1  81.3 
 Substandard drug contents are shown in bold. 
 * Reference drug. 
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on average 7.5 ± 6.0% lower after 6 months under accelerated 
testing conditions storage. The largest difference was found 
for methyldopa (Aldomet) from Pakistan (16.2%), followed 
by methyldopa from Kenya (15.4%) and atenolol (Betanorm; 
15%). The smallest difference was recorded for hydrochloro-
thiazide L&A from Kenya (0.5%). 
 DISCUSSION 
 This study showed poor quality of some antihypertensive 
drugs at purchase (2 of 10 formulations) and degradation of 
antihypertensive drugs under accelerated testing conditions. 
After 6 months of storage under accelerated testing conditions, 
8 of 10 formulations became substandard for the combined 
criteria of drug content and dissolution test. The presence of 
substandard quality antihypertensive drugs is probably not 
limited to Rwandan pharmacies but is likely the situation in 
many other SSA countries. The authors are not aware of a sim-
ilar or related study previously done on antihypertensive drugs 
in SSA, which shows how little the problem is addressed. 
 Data about substandard drugs in SSA remain scattered and 
heterogeneous in various drug classes. The literature reports 
4–100% of anti-infectious drugs substandard in content at the 
time of purchase in different SSA countries 12 such as Sudan, 7 
Kenya, 30 and Nigeria. 9,31,32 In this study, the percentage of con-
tent substandard drugs at purchase was 20%, whereas Risha 
and others 13 and Kayumba and others 10 reported in their 
series no formulation substandard in content at purchase. In 
this study, the drug content at purchase ranged from 44.5% to 
144.1% of the claimed content. This was because of two sub-
standard formulations most likely caused by a manufacturer 
error. The presence of substandard formulations caused by a 
manufacturer error has also been reported by other authors 
and ranged from 19% to 168% of the claimed content in 
antimalarial drugs in the Americas. 12 Apart from manufac-
turer errors, the large variability in percentage of substandard 
drugs may also be linked to the variation in time drugs were 
exposed to tropical climate conditions, which was not known 
at the time of purchase. Indeed, after 6 months at accelerated 
testing conditions, the percentage of substandard antihyper-
tensive drugs increased in this study from 20% to 80% and 
was higher than the 12% of substandard anti-infectious drugs 
from Tanzania and Rwanda. 10 
 This study also showed that both drug content and drug dis-
solution can be altered under accelerated testing conditions 
and that drugs being within the quality limits of drug content 
may have a decreased bioavailability as shown by substan-
dard dissolution profiles. The latter was the case for atenolol 
(Betanorm) in this study. 
 Currently, a struggle to increase the global pharmaceutical 
market is significantly being expanded in developing coun-
tries, 2 especially in SSA. During importation of new phar-
maceutical products, government and/or private pharmacies 
rely on the stability tests that are mandatory during formu-
 Table 4 
 Similarity factors of dissolution profiles 
Drug Dose (mg)
Values of similarity factor of dissolution profiles
Compared with the reference drug dissolution 
profile at similar storage time
Compared with the same drug formulation 
dissolution profile at purchase
 t = 0  t = 6 months  t = 6 months
At 
purchase
Long-term testing 
conditions
Accelerated testing 
conditions
Long-term testing 
conditions
Accelerated testing 
conditions
Atenolol
Tenormin * 100 Reference Reference Reference 58 57.8
Betanorm 100 50.4  38.2  32.1 52.5  38.3 
Catenol 100 55.7  31.8  28.2  46.9  43.1 
Captopril
Capoten * 25 Reference Reference Reference 75.2 54.3
Capoten * 50 Reference Reference Reference 52.4 61.6
Captopril Denk 25 60.9 50.2 63.7 57.9 56.1
Cetopril 25  35.1  37.1  29.1 65.8 53.5
Cetopril 50  39.1  34.2  30.2 51.7 61.1
Hydrochlorothiazide (HCTZ)
Esidrex * 25 Reference Reference Reference 74.5 77.2
HCTZ L&A 50  49.6  36.3  44.2 71.9  46.6 
HCTZ Cipla 50 68.7 58.3  37.5 68.8  41.3 
Methyldopa
Aldomet Belgium * 250 Reference Reference Reference 67 56.4
Methyldopa L&A 250 60  46.7  34.2 55.9 60.1
Aldomet Pakistan 250 52.5 50.6  33.3 81.8  41.3 
Propranolol
Inderal * 40 Reference Reference Reference 51.9  43.6 
Cepanolol 40 69.3 64.1  40.3  35.6  37.9 
 A similarity factor > 50 indicates that two dissolution profiles are pharmaceutically equivalent. Similarity factors < 50 are shown in bold. 
 *  Reference drug. 
 Figure 1.  Macroscopic aspect of methyldopa L&A at purchase 
time (left) and after 6-month storage at simulated tropical conditions 
(right). This figure appears in color at www.ajtmh.org. 
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lation development. 2,4,7,33 This study shows that probably not 
all manufacturers comply with this requirement. This is in line 
with the idea that substandard drug cases are under-reported 
and are often confused with counterfeit drugs, causing limited 
understanding of the extent of the problem. 19 This underlines 
the need for on-market drug quality monitoring. 
 In developing countries, governments often purchase drugs 
without adequate reference to quality standards. 19 In some 
settings, non-governmental organizations (NGOs) working in 
developing countries issue drug tenders without applying min-
imum quality assurance procedures. 19 Moreover, the capacity 
for technical evaluation or on-field drug quality monitoring 
is limited. 2 The World Health Organisation (WHO) estimates 
that only a few countries have fully functional drug regulatory 
systems. 19 Even if efforts are being made, in many SSA coun-
tries, relatively simple chromatographic or pharmacopeial 
methods for quality verification are not routinely available 34 
or used effectively. 35 Although drug registration is normally a 
prerequisite for purchase in resource-limited countries, autho-
rization to register a medicine is often granted based on a sim-
ple review of documents. Obviously, the quality is impossible 
to assure in the absence of proper controls that at minimum 
would include verification of information submitted for evalu-
ation through site inspections, review of batch documentation, 
and random analysis of drugs supplied. In developing coun-
tries, a pharmacovigilance system is very often lacking. The 
setting up of a functioning pharmacovigilance system, which 
allows for the rapid communication of problems and recall of 
harmful drugs, is a costly and complicated process that has to 
compete with many other pressing health system priorities in 
resource-limited settings. 19 
 The importance of substandard drugs may also be linked to 
low cost of those drugs, especially in the SSA settings, where 
the price of drugs is a major determinant of care accessibility 
and where drugs are paid out-of-pocket by patients. 
 This study has some limitations. A first limitation is the use 
of  in vitro dissolution tests as a surrogate for  in vivo bioavail-
ability.  In vitro dissolution is more rapid and much less expen-
sive than an  in vivo bioavailability study. However, whereas 
normal dissolution may suggest good bioavailability, 22 a sub-
standard dissolution profile does not automatically imply a 
low oral bioavailability. 23 The latter should be confirmed with 
an  in vivo bioavailability study. Another limitation may be 
linked to the unknown storage time and storage conditions of 
the drug samples before purchase that could have influenced 
the findings. However, because the quality of 8 of 10 formu-
lations was sufficient at the time of purchase and most of 
them degraded during storage, this limitation is likely of lesser 
importance. In addition, non-active ingredients (excipients) 
or their degradation products have not been investigated in 
this study and may harm human health as toxic ingredients. 19 
Because the packaging material of the different formulations 
was unknown to the authors, the possible effect of this param-
eter on drug stability could not be assessed. The findings from 
this study suggested that some pharmaceutical manufacturers 
do not take special measures for drugs marketed in climate 
Zone IVA or IVB. Risha and others 20 reported similar findings 
for different drug categories because several drug formula-
tions imported into Tanzania were not optimized for stability 
in a tropical climate. 
 In this study, medicines were bought from official pharma-
cies where drugs are stored in the original package. Apart 
from official pharmacies, medicines are sold on SSA mar-
kets per tablet without the original package, thereby increas-
ing the exposure to high humidity. It is likely that those drugs 
are more sensitive to quality degradation compared with the 
results found in this study. 
 Using drug content analysis and  in vitro dissolution tests, 
2 of 10 antihypertensive drug formulations were substandard 
at purchase. In addition, after 6 months of storage at accel-
erated testing (simulated tropical climate) conditions, 8 of 10 
test drugs were substandard for the combined criteria of drug 
content and dissolution test, whereas none of the reference 
drugs became substandard. This suggests a deleterious effect 
of tropical climate on the antihypertensive drug in Rwanda 
and probably also in other SSA countries sharing the same 
tropical climate. In this study, the hydrochlorothiazide formu-
lations were the most stable drug formulations. Because the 
use of drugs of substandard quality may alter treatment out-
come, this study shows the need for on-market drug quality 
monitoring. 
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